New CFO at Vitrolife
Mikael Engblom has been appointed as new Head of Vitrolife’s Accounting and Finance department and Investor Relations. Mikael has the last five years been working as Finance Controller at Vitrolife.
Mikael will assume his new position as per 1 October and replace Anne-Lie Sveder, present CFO at Vitrolife, who has decided to terminate her employment at Vitrolife to work in other business.
Gothenburg, July 15, 2011
VITROLIFE AB (publ)
Magnus Nilsson
CEO
.
Queries should be addressed to:
Magnus Nilsson, CEO; phone +46 31 721 80 61
Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keep them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.
Vitrolife today has approximately 220 employees and its products are sold in more than 85 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France, Italy, United Kingdom and Japan. Production facilities are located in Sweden and the USA. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
_________________________________________________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Website: www.vitrolife.com.
Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on Wednesday July 15, at 2:00 p.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
